Allergy Therapeutics Net Assets
Allergy Therapeutics net assets. Based on the latest financial reports, Allergy Therapeutics (AGY) has net assets worth GBX4.25 Million GBX (≈ $516.98 USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX71.00 Million ≈ $8.64K USD) and total liabilities (GBX66.75 Million ≈ $8.12K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Allergy Therapeutics to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX4.25 Million |
| % of Total Assets | 5.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | -158.09% |
| 10-Year Change | -192.97% |
| Growth Volatility | 246.32 |
Net Assets of Allergy Therapeutics (2002–2025)
Net assets of Allergy Therapeutics from 2002 to 2025. This chart illustrates how Allergy Therapeutics's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Allergy Therapeutics to measure how much of total assets are equity-financed.
Annual Net Assets for Allergy Therapeutics (2002–2025)
The table below shows the annual net assets of Allergy Therapeutics from 2002 to 2025. For live market cap and overall valuation, see Allergy Therapeutics market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | GBX-28.19 Million ≈ $-3.43K |
-860.12% |
| 2024-06-30 | GBX3.71 Million ≈ $451.28 |
+79.53% |
| 2023-06-30 | GBX2.07 Million ≈ $251.37 |
-94.53% |
| 2022-06-30 | GBX37.77 Million ≈ $4.59K |
-22.19% |
| 2021-06-30 | GBX48.53 Million ≈ $5.91K |
+10.85% |
| 2020-06-30 | GBX43.78 Million ≈ $5.33K |
+16.57% |
| 2019-06-30 | GBX37.56 Million ≈ $4.57K |
+63.05% |
| 2018-06-30 | GBX23.03 Million ≈ $2.80K |
-23.13% |
| 2017-06-30 | GBX29.96 Million ≈ $3.65K |
-1.18% |
| 2016-06-30 | GBX30.32 Million ≈ $3.69K |
-12.03% |
| 2015-06-30 | GBX34.47 Million ≈ $4.19K |
+128.65% |
| 2014-06-30 | GBX15.07 Million ≈ $1.83K |
+2.75% |
| 2013-06-30 | GBX14.67 Million ≈ $1.79K |
+0.54% |
| 2012-06-30 | GBX14.59 Million ≈ $1.78K |
+582.19% |
| 2011-06-30 | GBX2.14 Million ≈ $260.25 |
-44.96% |
| 2010-06-30 | GBX3.89 Million ≈ $472.81 |
+116.77% |
| 2009-06-30 | GBX-23.18 Million ≈ $-2.82K |
-105.28% |
| 2008-06-30 | GBX-11.29 Million ≈ $-1.37K |
-231.34% |
| 2007-06-30 | GBX8.60 Million ≈ $1.05K |
-73.71% |
| 2006-06-30 | GBX32.70 Million ≈ $3.98K |
+62.83% |
| 2005-06-30 | GBX20.08 Million ≈ $2.44K |
+183.83% |
| 2004-06-30 | GBX7.08 Million ≈ $860.94 |
+27.56% |
| 2003-06-30 | GBX5.55 Million ≈ $674.91 |
+226.13% |
| 2002-06-30 | GBX-4.40 Million ≈ $-535.11 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Allergy Therapeutics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15545200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Allergy Therapeutics Net Assets Breakdown (June 2025)
Allergy Therapeutics net assets breakdown by equity component as of June 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX4.77 Million | % |
| Other Comprehensive Income | GBX7.50 Million | % |
| Other Components | GBX154.64 Million | % |
| Total Equity | GBX-28.19 Million | 100.00% |
Allergy Therapeutics Competitors by Market Cap
The table below lists competitors of Allergy Therapeutics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SEALAND CAP. GA. LS-0001
F:7KM
|
$984.05K |
|
Ampli SA w upadlosci ukladowej
WAR:APL
|
$984.55K |
|
Rapid Nutrition PLC
PA:ALRPD
|
$985.01K |
|
Capital Gearing Trust
LSE:CGT
|
$986.55K |
|
Brave Bison Group PLC
LSE:BBSN
|
$982.20K |
|
Gentlemens Equity S.A.
PA:MLGEQ
|
$978.53K |
|
Global Energy Metals Corp
V:GEMC
|
$977.61K |
|
Venture Life Group PLC
LSE:VLG
|
$977.42K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Allergy Therapeutics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,709,000 to -28,193,000, a change of -31,902,000 (-860.1%).
- Net loss of 40,132,000 reduced equity.
- Other comprehensive income increased equity by 6,189,000.
- Other factors increased equity by 2,041,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-40.13 Million | -142.35% |
| Other Comprehensive Income | GBX6.19 Million | +21.95% |
| Other Changes | GBX2.04 Million | +7.24% |
| Total Change | GBX- | -860.12% |
Book Value vs Market Value Analysis
This analysis compares Allergy Therapeutics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-06-30 | GBX-0.10 | GBX1.28 | x |
| 2003-06-30 | GBX0.09 | GBX1.28 | x |
| 2004-06-30 | GBX0.14 | GBX1.28 | x |
| 2005-06-30 | GBX0.35 | GBX1.28 | x |
| 2006-06-30 | GBX0.49 | GBX1.28 | x |
| 2007-06-30 | GBX0.10 | GBX1.28 | x |
| 2008-06-30 | GBX-0.14 | GBX1.28 | x |
| 2009-06-30 | GBX-0.28 | GBX1.28 | x |
| 2010-06-30 | GBX0.01 | GBX1.28 | x |
| 2011-06-30 | GBX0.01 | GBX1.28 | x |
| 2012-06-30 | GBX0.04 | GBX1.28 | x |
| 2013-06-30 | GBX0.03 | GBX1.28 | x |
| 2014-06-30 | GBX0.03 | GBX1.28 | x |
| 2015-06-30 | GBX0.07 | GBX1.28 | x |
| 2016-06-30 | GBX0.05 | GBX1.28 | x |
| 2017-06-30 | GBX0.05 | GBX1.28 | x |
| 2018-06-30 | GBX0.04 | GBX1.28 | x |
| 2019-06-30 | GBX0.06 | GBX1.28 | x |
| 2020-06-30 | GBX0.07 | GBX1.28 | x |
| 2021-06-30 | GBX0.07 | GBX1.28 | x |
| 2022-06-30 | GBX0.06 | GBX1.28 | x |
| 2023-06-30 | GBX0.00 | GBX1.28 | x |
| 2024-06-30 | GBX0.00 | GBX1.28 | x |
| 2025-06-30 | GBX-0.01 | GBX1.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Allergy Therapeutics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -72.91%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-147.62%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | -30.80% | 1.56x | 0.00x | GBX-4.02 Million |
| 2003 | 93.31% | 29.87% | 1.55x | 2.01x | GBX4.62 Million |
| 2004 | 17.21% | 6.77% | 1.60x | 1.59x | GBX510.40K |
| 2005 | -10.91% | -10.63% | 0.77x | 1.33x | GBX-4.20 Million |
| 2006 | -18.88% | -26.20% | 0.62x | 1.16x | GBX-9.44 Million |
| 2007 | -270.54% | -90.34% | 1.07x | 2.79x | GBX-24.12 Million |
| 2008 | 0.00% | -65.43% | 1.34x | 0.00x | GBX-19.17 Million |
| 2009 | 0.00% | -31.16% | 1.71x | 0.00x | GBX-9.45 Million |
| 2010 | 15.08% | 1.44% | 1.40x | 7.49x | GBX197.40K |
| 2011 | -124.45% | -6.41% | 1.36x | 14.32x | GBX-2.88 Million |
| 2012 | 5.64% | 1.99% | 1.49x | 1.90x | GBX-636.20K |
| 2013 | 3.65% | 1.36% | 1.36x | 1.97x | GBX-931.10K |
| 2014 | 4.92% | 1.77% | 1.48x | 1.88x | GBX-766.50K |
| 2015 | 0.31% | 0.25% | 0.85x | 1.47x | GBX-3.34 Million |
| 2016 | -43.11% | -26.95% | 0.86x | 1.87x | GBX-16.10 Million |
| 2017 | -8.28% | -3.87% | 1.12x | 1.91x | GBX-5.48 Million |
| 2018 | -32.70% | -11.02% | 1.34x | 2.21x | GBX-9.84 Million |
| 2019 | 9.23% | 4.70% | 1.08x | 1.82x | GBX-288.80K |
| 2020 | 16.12% | 9.03% | 0.91x | 1.97x | GBX2.68 Million |
| 2021 | 5.95% | 3.42% | 0.96x | 1.81x | GBX-1.97 Million |
| 2022 | -36.48% | -18.93% | 1.00x | 1.93x | GBX-17.55 Million |
| 2023 | -2084.75% | -72.28% | 0.89x | 32.32x | GBX-43.28 Million |
| 2024 | -1084.28% | -72.86% | 0.85x | 17.48x | GBX-40.59 Million |
| 2025 | 0.00% | -72.91% | 0.81x | 0.00x | GBX-37.31 Million |
Industry Comparison
This section compares Allergy Therapeutics's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,249,495,846
- Average return on equity (ROE) among peers: -2.51%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Allergy Therapeutics (AGY) | GBX4.25 Million | 0.00% | 15.71x | $982.37K |
| Animalcare Group Plc (ANCR) | $78.80 Million | -0.10% | 0.40x | $2.81 Million |
| Alliance Pharma plc (APH) | $6.67 Million | -48.15% | 5.96x | $4.26 Million |
| Celadon Pharmaceuticals PLC (CEL) | $6.41 Million | -74.61% | 0.03x | $112.25K |
| Chill Brands Group PLC (CHLL) | $-1.23 Million | 0.00% | 0.00x | $101.80K |
| Eco Animal Health Group Plc (EAH) | $98.17 Million | 10.76% | 0.16x | $681.55K |
| HUTCHMED China Ltd (HCM) | $83.65 Million | 4.35% | 1.50x | $21.47 Million |
| Hikma Pharmaceuticals PLC (HIK) | $1.35 Billion | 18.64% | 0.92x | $44.46 Million |
| Haleon PLC (HLN) | $27.41 Billion | 2.39% | 0.30x | $367.23 Million |
| Indivior PLC (INDV) | $209.00 Million | 64.11% | 6.90x | $18.79 Million |
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more